{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Antigène HLA-B13 : Questions médicales les plus fréquentes",
"headline": "Antigène HLA-B13 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Antigène HLA-B13 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-20",
"dateModified": "2025-02-14",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Antigène HLA-B13"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Antigènes HLA-B",
"url": "https://questionsmedicales.fr/mesh/D015235",
"about": {
"@type": "MedicalCondition",
"name": "Antigènes HLA-B",
"code": {
"@type": "MedicalCode",
"code": "D015235",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.050.705.552.450.380"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Antigène HLA-B13",
"alternateName": "HLA-B13 Antigen",
"code": {
"@type": "MedicalCode",
"code": "D059908",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Apostolos P Georgopoulos",
"url": "https://questionsmedicales.fr/author/Apostolos%20P%20Georgopoulos",
"affiliation": {
"@type": "Organization",
"name": "The HLA Research Group, Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN, USA."
}
},
{
"@type": "Person",
"name": "Lisa M James",
"url": "https://questionsmedicales.fr/author/Lisa%20M%20James",
"affiliation": {
"@type": "Organization",
"name": "The HLA Research Group, Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN, USA."
}
},
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Arie Admon",
"url": "https://questionsmedicales.fr/author/Arie%20Admon",
"affiliation": {
"@type": "Organization",
"name": "Faculty of Biology, Technion Israel Institute of Technology, Haifa, Israel admon@technion.ac.il Michael.peled@sheba.health.gov.il."
}
},
{
"@type": "Person",
"name": "Spyros A Charonis",
"url": "https://questionsmedicales.fr/author/Spyros%20A%20Charonis",
"affiliation": {
"@type": "Organization",
"name": "The HLA Research Group, Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Programmed cell death-1 blockade therapy in melanoma: Resistance mechanisms and combination strategies.",
"datePublished": "2023-01-24",
"url": "https://questionsmedicales.fr/article/36645031",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/exd.14750"
}
},
{
"@type": "ScholarlyArticle",
"name": "MicroRNAs Targeting Programmed Cell Death Protein 1 (PD-1) Promote Natural Killer Cell Exhaustion in Rheumatoid Arthritis.",
"datePublished": "2022-12-24",
"url": "https://questionsmedicales.fr/article/36640056",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.18502/ijaai.v21i6.11524"
}
},
{
"@type": "ScholarlyArticle",
"name": "Differential expression of programmed death 1 (PD-1) on various immune cells and its role in human leprosy.",
"datePublished": "2023-04-21",
"url": "https://questionsmedicales.fr/article/37153623",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1138145"
}
},
{
"@type": "ScholarlyArticle",
"name": "A High Programmed Cell Death Protein 1 Hormone Receptor Score on Skin Biopsy is Associated with Sézary Syndrome Diagnosis: A Study of 91 Patients with Erythroderma.",
"datePublished": "2022-09-06",
"url": "https://questionsmedicales.fr/article/35758515",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2340/actadv.v102.1062"
}
},
{
"@type": "ScholarlyArticle",
"name": "Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.",
"datePublished": "2022-11-25",
"url": "https://questionsmedicales.fr/article/36442821",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.actbio.2022.11.043"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Antigènes",
"item": "https://questionsmedicales.fr/mesh/D000941"
},
{
"@type": "ListItem",
"position": 4,
"name": "Isoantigènes",
"item": "https://questionsmedicales.fr/mesh/D007519"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antigènes d'histocompatibilité",
"item": "https://questionsmedicales.fr/mesh/D006649"
},
{
"@type": "ListItem",
"position": 6,
"name": "Antigènes HLA",
"item": "https://questionsmedicales.fr/mesh/D006680"
},
{
"@type": "ListItem",
"position": 7,
"name": "Antigènes HLA-B",
"item": "https://questionsmedicales.fr/mesh/D015235"
},
{
"@type": "ListItem",
"position": 8,
"name": "Antigène HLA-B13",
"item": "https://questionsmedicales.fr/mesh/D059908"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Antigène HLA-B13 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Antigène HLA-B13",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Antigène HLA-B13",
"description": "Comment diagnostiquer la présence de HLA-B13 ?\nQuels tests sont utilisés pour HLA-B13 ?\nHLA-B13 est-il associé à des maladies spécifiques ?\nPeut-on détecter HLA-B13 chez tous les individus ?\nQuel rôle joue HLA-B13 dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D059908?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Antigène HLA-B13",
"description": "Quels symptômes sont liés à HLA-B13 ?\nHLA-B13 cause-t-il des symptômes directs ?\nY a-t-il des symptômes spécifiques à HLA-B13 ?\nHLA-B13 est-il lié à des symptômes allergiques ?\nLes symptômes varient selon l'ethnicité ?",
"url": "https://questionsmedicales.fr/mesh/D059908?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Antigène HLA-B13",
"description": "Peut-on prévenir les maladies liées à HLA-B13 ?\nY a-t-il des mesures préventives spécifiques ?\nLa vaccination aide-t-elle contre HLA-B13 ?\nLes tests génétiques peuvent-ils prévenir des maladies ?\nL'éducation sur HLA-B13 est-elle importante ?",
"url": "https://questionsmedicales.fr/mesh/D059908?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Antigène HLA-B13",
"description": "Quels traitements sont disponibles pour les maladies liées à HLA-B13 ?\nHLA-B13 influence-t-il le choix du traitement ?\nY a-t-il des traitements spécifiques pour HLA-B13 ?\nLes traitements sont-ils efficaces pour HLA-B13 ?\nDes thérapies géniques sont-elles envisagées pour HLA-B13 ?",
"url": "https://questionsmedicales.fr/mesh/D059908?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Antigène HLA-B13",
"description": "Quelles complications peuvent survenir avec HLA-B13 ?\nHLA-B13 augmente-t-il le risque de cancer ?\nLes complications sont-elles réversibles ?\nHLA-B13 influence-t-il la gravité des maladies ?\nY a-t-il des complications spécifiques à HLA-B13 ?",
"url": "https://questionsmedicales.fr/mesh/D059908?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Antigène HLA-B13",
"description": "Quels sont les facteurs de risque pour HLA-B13 ?\nL'ethnicité influence-t-elle HLA-B13 ?\nLes infections augmentent-elles le risque lié à HLA-B13 ?\nLe mode de vie affecte-t-il HLA-B13 ?\nY a-t-il des tests pour évaluer les facteurs de risque ?",
"url": "https://questionsmedicales.fr/mesh/D059908?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la présence de HLA-B13 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un test sanguin pour déterminer le typage HLA est utilisé pour diagnostiquer HLA-B13."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour HLA-B13 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de typage HLA, comme la PCR et le séquençage, sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "HLA-B13 est-il associé à des maladies spécifiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, HLA-B13 est lié à certaines maladies auto-immunes et infections virales."
}
},
{
"@type": "Question",
"name": "Peut-on détecter HLA-B13 chez tous les individus ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, HLA-B13 est présent chez une partie de la population, selon l'ethnicité."
}
},
{
"@type": "Question",
"name": "Quel rôle joue HLA-B13 dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il aide à évaluer la compatibilité pour les greffes et à identifier des risques de maladies."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à HLA-B13 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient selon les maladies associées, comme des douleurs articulaires ou éruptions."
}
},
{
"@type": "Question",
"name": "HLA-B13 cause-t-il des symptômes directs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, HLA-B13 lui-même ne cause pas de symptômes, mais il est associé à des maladies."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques à HLA-B13 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes dépendent des conditions associées, pas de HLA-B13 directement."
}
},
{
"@type": "Question",
"name": "HLA-B13 est-il lié à des symptômes allergiques ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "HLA-B13 n'est pas directement lié aux allergies, mais à des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Les symptômes varient selon l'ethnicité ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la prévalence de HLA-B13 et les maladies associées peuvent varier selon l'ethnicité."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les maladies liées à HLA-B13 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un suivi médical régulier peut aider à détecter précocement."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives spécifiques ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des mesures préventives incluent un mode de vie sain et la gestion du stress."
}
},
{
"@type": "Question",
"name": "La vaccination aide-t-elle contre HLA-B13 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vaccination peut aider à prévenir certaines infections, mais pas directement HLA-B13."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils prévenir des maladies ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier les risques et permettre une surveillance préventive."
}
},
{
"@type": "Question",
"name": "L'éducation sur HLA-B13 est-elle importante ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation sur HLA-B13 et ses implications peut aider à mieux gérer les risques."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les maladies liées à HLA-B13 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des immunosuppresseurs et des thérapies ciblées selon la maladie."
}
},
{
"@type": "Question",
"name": "HLA-B13 influence-t-il le choix du traitement ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la présence de HLA-B13 peut influencer le choix des traitements immunologiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements spécifiques pour HLA-B13 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitement spécifique pour HLA-B13, mais pour les maladies associées."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces pour HLA-B13 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité des traitements dépend de la maladie associée et de la réponse individuelle."
}
},
{
"@type": "Question",
"name": "Des thérapies géniques sont-elles envisagées pour HLA-B13 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours sur les thérapies géniques, mais elles ne sont pas encore disponibles."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec HLA-B13 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des maladies auto-immunes et des réactions aux greffes."
}
},
{
"@type": "Question",
"name": "HLA-B13 augmente-t-il le risque de cancer ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent un lien entre HLA-B13 et un risque accru de certains cancers."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "HLA-B13 influence-t-il la gravité des maladies ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, HLA-B13 peut influencer la gravité et l'évolution de certaines maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications spécifiques à HLA-B13 ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications spécifiques dépendent des maladies associées, pas de HLA-B13 lui-même."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour HLA-B13 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, l'ethnicité et des infections virales."
}
},
{
"@type": "Question",
"name": "L'ethnicité influence-t-elle HLA-B13 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la prévalence de HLA-B13 varie selon les groupes ethniques et les populations."
}
},
{
"@type": "Question",
"name": "Les infections augmentent-elles le risque lié à HLA-B13 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections peuvent déclencher des maladies auto-immunes chez les porteurs de HLA-B13."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il HLA-B13 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut réduire le risque de maladies associées à HLA-B13."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests pour évaluer les facteurs de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests génétiques et des évaluations médicales peuvent aider à identifier les risques."
}
}
]
}
]
}
Melanoma is a highly aggressive tumor derived from melanocytes. In recent years, the incidence and mortality of melanoma have gradually increased, seriously threatening human health. Classic treatment...
Natural killer (NK) cells play a role in the pathogenesis of rheumatoid arthritis (RA). Upregulated levels of programmed cell death protein 1 (PD-1) is a sign of exhausted NK cells that could be regul...
Erythroderma is challenging to diagnose. The aim of this single-centre retrospective study was to identify factors that can be used to improve the diagnosis of erythroderma. Among 91 patients with ery...
Immune checkpoint blockade therapy targeting programmed death-1 (PD-1) or its major ligand programmed death-ligand 1 (PD-L1) has achieved remarkable success in the treatment of several tumors, includi...
The immune system uses various immune checkpoint axes to adjust responses, support homeostasis, and deter self-reactivity and autoimmunity. Nevertheless, non-small-cell lung carcinoma (NSCLC) can use ...
Pembrolizumab or nivolumab plus chemotherapy was approved as a first-line treatment for high programmed cell death ligand 1 (PD-L1)-expressing esophageal squamous cell carcinoma (ESCC) by the European...
Post hoc analysis of the Chinese JUPITER-06 study focusing on efficacy stratified by PD-L1 tumor proportion score (TPS; using JS311 antibody) was conducted. Electronic databases were searched to ident...
The post hoc analysis of JUPITER-06 showed more prominent clinical benefit with PD-1 antibody plus chemotherapy than with chemotherapy alone in both the high and low PD-L1-expressing subgroups. Five r...
This study provided novel evidence supporting the superiority of PD-1 antibody plus chemotherapy to chemotherapy alone in patients with advanced ESCC with low PD-L1 expression. Further studies of pred...
Major depression (MD) may be associated with inflammation and immunity. PD-1 (programmed death-1), PD-L1 (programmed death-ligand 1) and PD-L2 (programmed death-ligand 2) are among the inhibitory immu...
During a period of 2 years, patients with MD and healthy controls were recruited from a medical centre in this study. The diagnosis of MD was established according to the DSM-5 criteria. The severity ...
A total of 54 patients with MD and 38 healthy controls were recruited. According to the analyses, there is a significantly higher PD-L2 level in MD than in healthy controls and lower PD-1 level after ...
It was found that PD-1 pathway might play an important role in MD. We need a large sample to prove these results in the future....
Tumor-infiltrating lymphocytes are detectable in up to 75% of triple-negative breast cancer. The composition of these infiltrates may influence prognosis and is not known regarding regulatory or effec...
This was a retrospective observational study. Clinical and pathological data from 38 triple-negative breast cancer patients treated with neoadjuvant chemotherapy at the University Hospital (HUCFF/UFRJ...
Statistically significant changes in stromal tumor-infiltrating lymphocyte categories were observed before and post-neoadjuvant chemotherapy, with 32% of intermediate cases becoming high. The correlat...
In this study, we observed that chemotherapy significantly increases stromal tumor-infiltrating lymphocytes, CD8 T cells, as well as CD8/FoxP3 ratio. Most importantly, programmed cell death protein 1 ...
Melanoma is widely treated with programmed cell death-1 (PD-1) inhibitors. As part of their anti-tumor immunity effect, they increase the susceptibility to cutaneous immune-related adverse events (cIR...